Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival.
Higuchi T, Sugisawa N, Park JH, Sun Y, Zhu G, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.
Higuchi T, et al. Among authors: miwa s.
Transl Oncol. 2020 Oct;13(10):100826. doi: 10.1016/j.tranon.2020.100826. Epub 2020 Jul 10.
Transl Oncol. 2020.
PMID: 32659740
Free PMC article.